BIOSIMILARS, STC Biologics
STC Biologics announces expansion of its analytical capabilities & bioassays to include GMP Testing
Cambridge (June 7th, 2016) STC Biologics, Inc., a biologics and targeted nanoparticle contract development company has expanded its development capabilities to include Quality Systems for GMP release and stability testing. In March 2016, STC Biologics, Inc. launched its release and stability testing GMP facility after a successful QP audit to offer services in: GMP Cell… Read More
BIOSIMILARS, STC Biologics
BIOSIMILARS: AN EMERGING DRUG CLASS TAKES FLIGHT
Biologics represent the fastest growing segment of approved pharmaceuticals. Showing an increase of 10.6% compound annual growth rate and market size of USD234 billion in 2014, these products have contributed to a healthcare-spending crisis that has threated the sustainability of healthcare systems worldwide and patient access to essential medicines. Biosimilars offer one way to reduce… Read More